Life-threatening infections following rituximab therapy in renal transplant patients with mixed cryoglobulinemia

Basse, Grégoire; Ribes, D; Kamar, Nassim; Esposito, Laure; Rostaing, Lionel

doi:10.5414/cnp66395

Cited by 13 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Besides these series, there is a growing series of case reports of infections in solid organ transplant recipients after receiving rituximab, including pneumocystis, 29,30 bacterial fasciitis, Cryptococcus, and disseminated herpes. 110…”

Section: Infections Associated With Rituximab Use In Solid Organ Tranmentioning

confidence: 99%

Rituximab-Associated Infections

Gea-Banacloche

2010

Seminars in Hematology

232

141

View full text Add to dashboard Cite

Section: Infections Associated With Rituximab Use In Solid Organ Tranmentioning

confidence: 99%

Rituximab-Associated Infections

Gea-Banacloche

2010

Seminars in Hematology

232

141

View full text Add to dashboard Cite

“…Rituximab has proven to be an effective treatment for de novo MCN in transplant patients (81) but in some transplant patients rituximab may cause life-threatening infections (82).…”

Section: Mixed Cryoglobulinemic Nephritismentioning

confidence: 99%

Recurrence of Secondary Glomerular Disease after Renal Transplantation

Ponticelli¹,

Moroni

Glassock

2011

Clinical Journal of the American Society of Nephrology

View full text Add to dashboard Cite

SummaryThe risk of a posttransplant recurrence of secondary glomerulonephritis (GN) is quite variable. Histologic recurrence is frequent in lupus nephritis, but the lesions are rarely severe and usually do not impair the longterm graft outcome. Patients with Henoch-Schonlein nephritis have graft survival similar to that of other renal diseases, although recurrent Henoch-Schonlein nephritis with extensive crescents has a poor prognosis. Amyloid light-chain amyloidosis recurs frequently in renal allografts but it rarely causes graft failure. Amyloidosis secondary to chronic inflammation may also recur, but this is extremely rare in patients with Behcet's disease or in those with familial Mediterranean fever, when the latter are treated with colchicine. Double organ transplantation (liver/kidney; heart/kidney), chemotherapy, and autologous stem cell transplantation may be considered in particular cases of amyloidosis, such as hereditary amyloidosis or multiple myeloma. There is little experience with renal transplantation in light-chain deposition disease, fibrillary/ immunotactoid GN, or mixed cryoglobulinemic nephritis but successful cases have been reported. Diabetic nephropathy often recurs but usually only after many years. Recurrence in patients with small vessel vasculitis is unpredictable but can cause graft failure. However, in spite of recurrence, patient and graft survival rates are similar in patients with small vessel vasculitis compared with those with other renal diseases. Many secondary forms of GN no longer represent a potential contraindication to renal transplantation. The main issues in transplantation of patients with secondary GN are the infectious, cardiovascular, or hepatic complications associated with the original disease or its treatment.

show abstract

“…Cryoglobulins are immunoglobulins that precipitate in a cold environment, can produce systemic organ damage [ 3 , 4 ], and are known as a relatively rare cause of renal failure. Previous case reports have shown the recurrence of cryoglobulinemia in a renal allograft in patients who received a kidney transplant [ 3 , 5 , 6 ]. Those past experiences may cause doctors to hesitate to perform transplantation.…”

Section: Introductionmentioning

confidence: 99%

Successful renal transplantation to a recipient with type II cryoglobulinemia: a case report

et al. 2018

View full text Add to dashboard Cite

BackgroundRecurrence of glomerulonephritis is an important risk factor for renal graft dysfunction. Cryoglobulinemia is known as a relatively rare cause of renal failure, and doctors are usually hesitant to perform transplantation on a recipient with cryoglobulinemia because of the risk for graft loss. We present a case of renal transplantation on a patient with organ manifestations of type II cryoglobulinemia.Case presentationAt the age of 44 years, the patient developed acute kidney injury and purpura on the lower extremities with type II cryoglobulinemia after interferon therapy for hepatitis C virus. Cryoglobulinemic glomerulonephritis was suspected; however, despite immunosuppressive therapy combined with plasmapheresis, she eventually needed hemodialysis treatment. She was referred to us at the age of 49 years for renal transplantation. Cryocrit was 14% and the organ manifestations persisted, including the lower extremity purpura and neurologic symptoms. After monitoring and confirming sufficient suppression of cryoglobulin concentration by immunosuppressive treatment with prednisolone, cyclophosphamide, and rituximab combined with plasmapheresis, the operation was performed. After transplantation, the cryoglobulin concentration was continuously monitored, and plasmapheresis and rituximab infusion were performed as appropriate. Her graft function has remained stable for 2 years and 6 months.ConclusionOur case suggested that a patient with cryoglobulinemia and persistent organ manifestations can receive a renal graft if the cryoglobulin concentration is sufficiently controlled by pretransplant treatment.

show abstract

Life-threatening infections following rituximab therapy in renal transplant patients with mixed cryoglobulinemia

Cited by 13 publications

References 0 publications

Rituximab-Associated Infections

Rituximab-Associated Infections

Recurrence of Secondary Glomerular Disease after Renal Transplantation

Successful renal transplantation to a recipient with type II cryoglobulinemia: a case report

Contact Info

Product

Resources

About